Skip to main content
Poltreg S.A. logo

Poltreg S.A. — Investor Relations & Filings

Ticker · PTG ISIN · PLPLTRG00038 LEI · 259400XSAJTERJ42VZ86 WAR Professional, scientific and technical activities
Open in API
Filings indexed 359 across all filing types
Latest filing 2026-05-13 Major Shareholding Noti…
Country PL Poland
Listing WAR PTG

About Poltreg S.A.

https://poltreg.com/

Poltreg S.A. is a clinical-stage biotechnology company developing cellular therapies for a range of autoimmune diseases. The company specializes in treatments based on T-regulatory cells (Tregs), with an advanced pipeline of both polyclonal and engineered cell therapies. Its lead product, PTG-007, is an autologous Treg treatment being investigated for Type 1 Diabetes and Multiple Sclerosis. Poltreg is also advancing next-generation engineered therapies, including Chimeric Antigen Receptor T-regulatory cells (CAR-Tregs), for neuroinflammatory conditions such as Multiple Sclerosis and Amyotrophic Lateral Sclerosis (ALS). The company operates its own state-of-the-art, cGMP-certified manufacturing facility to produce its advanced therapy medicinal products.

Recent filings

Filing Released Lang Actions
Zawiadomienie od PAAN Capital o zmianie udziału w ogólnej liczby głosów w PolTREG S.A. Podstawa prawna: Art. 70 pkt 1 Ustawy o ofercie - nabycie lub zbycie znacznego pakietu akcji - Content (PL)
Major Shareholding Notification Classification · 85% confidence The document is a current report informing about a notification from PAAN Capital concerning a change in its percentage of voting rights in the company due to return of loaned shares. This is a classic major shareholding notification (crossing thresholds or changes in significant share ownership).
2026-05-13 Polish
Zawiadomienie PAAN Capital
Director's Dealing Classification · 95% confidence The document is a notification under MAR Article 19, listing a senior manager/person closely related, the issuer details, and the specifics of a share transaction (loan return) including instrument code, volume, date, and off-market venue. This matches an insider dealing disclosure by directors/executives. Therefore, it is classified as a Director’s Dealing (insider trade) report.
2026-05-13 Polish
Powiadomienie od PAAN Capital o transakcji na akcjach Spółki otrzymane w trybie art. 19 MAR - Content (PL)
Regulatory Filings Classification · 65% confidence The document is a short regulatory announcement in which the company informs about receipt of a notification under Article 19(1) of the EU Market Abuse Regulation related to share loan return, referencing prior current reports. It does not contain financial statements or substantive report content to qualify as an interim or full report, nor is it soliciting votes, presenting AGM materials, or announcing dividends. It is a general compliance/regulatory update, so it falls under Regulatory Filings (RNS).
2026-05-13 Polish
PolTREG Raport kwartalny Q1
Interim / Quarterly Report Classification · 98% confidence The document is a comprehensive quarterly financial report (“Kwartalny raport finansowy”) for Q1 2026, containing full interim condensed financial statements (income statement, balance sheet, cash flows, equity changes), selected financial data, notes under IFRS, and management discussion of operations. It is not merely an announcement or a presentation but the actual condensed financial report for a quarter. This fits the definition of an Interim/Quarterly Report (IR). Q1 2026
2026-05-11 Polish
Zmiana terminu publikacji raportu okresowego za I kwartał 2026 rok. - Content (PL)
Regulatory Filings
2026-05-08 Polish
Informacja nt. rekomendowania przez Agencję Badań Medycznych dofinansowania projektu badawczo-rozwojowego, w którym PolTREG S.A. uczestniczy jako konsorcjant - Content (PL)
Regulatory Filings
2026-05-05 Polish

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.